Answer
Donanemab’s most commonly reported adverse reactions were ARIA-E, ARIA-H and headache: respectively 24.4%, 31.3% and 13.1% in the studied combined population, and 20.8%, 26.7% and 13.5% in the indicated population.
Sources for this answer
- Kisunla 350 mg concentrate for solution for infusionEli Lilly and Company Limited · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked